🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 24/08/2007 | 36,25 | 37,36 | 36,25 | 37,34 | +2,64% | 3,06% | 857.700 |
| 23/08/2007 | 37,00 | 37,32 | 36,13 | 36,38 | -1,57% | 3,22% | 926.200 |
| 22/08/2007 | 37,90 | 37,93 | 36,80 | 36,96 | -1,20% | 2,98% | 931.800 |
| 21/08/2007 | 36,56 | 38,00 | 36,56 | 37,41 | +1,66% | 3,94% | 1.403.900 |
| 20/08/2007 | 36,45 | 36,91 | 35,90 | 36,80 | -0,19% | 2,77% | 1.516.700 |
| 17/08/2007 | 35,75 | 36,91 | 35,00 | 36,87 | +3,19% | 5,34% | 2.261.100 |
| 16/08/2007 | 34,70 | 36,21 | 34,23 | 35,73 | +2,38% | 5,71% | 2.280.900 |
| 15/08/2007 | 34,90 | 36,76 | 34,70 | 34,90 | -0,57% | 5,90% | 1.737.700 |
| 14/08/2007 | 36,20 | 36,29 | 35,00 | 35,10 | -2,36% | 3,56% | 1.226.000 |
| 13/08/2007 | 37,00 | 37,04 | 35,50 | 35,95 | -1,75% | 4,16% | 1.822.700 |
| 10/08/2007 | 37,97 | 38,00 | 35,50 | 36,59 | -4,19% | 6,58% | 4.120.500 |
| 09/08/2007 | 37,60 | 39,18 | 37,48 | 38,19 | -0,81% | 4,52% | 4.071.800 |
| 08/08/2007 | 37,99 | 39,80 | 37,40 | 38,50 | +2,15% | 6,32% | 4.505.000 |
| 07/08/2007 | 35,62 | 38,25 | 35,45 | 37,69 | +5,40% | 7,86% | 5.756.000 |
| 06/08/2007 | 33,49 | 36,24 | 33,23 | 35,76 | +7,65% | 8,99% | 4.501.500 |
| 03/08/2007 | 33,24 | 33,76 | 32,83 | 33,22 | +0,15% | 2,80% | 2.607.400 |
| 02/08/2007 | 32,88 | 33,23 | 32,54 | 33,17 | +1,75% | 2,10% | 1.309.300 |
| 01/08/2007 | 32,20 | 32,76 | 31,98 | 32,60 | +0,93% | 2,42% | 1.681.500 |
| 31/07/2007 | 32,90 | 33,25 | 32,30 | 32,30 | -0,92% | 2,89% | 1.986.100 |
| 30/07/2007 | 32,40 | 32,85 | 32,09 | 32,60 | +0,49% | 2,35% | 2.860.300 |
| 27/07/2007 | 32,88 | 33,10 | 31,85 | 32,44 | -1,19% | 3,80% | 2.949.100 |
| 26/07/2007 | 32,91 | 33,85 | 32,39 | 32,83 | -0,45% | 4,44% | 3.861.600 |
| 25/07/2007 | 30,19 | 33,00 | 30,15 | 32,98 | +10,97% | 9,44% | 6.130.500 |
| 24/07/2007 | 29,09 | 29,99 | 28,88 | 29,72 | +1,64% | 3,82% | 2.363.800 |
| 23/07/2007 | 29,52 | 29,60 | 28,90 | 29,24 | -0,27% | 2,37% | 1.341.600 |
| 20/07/2007 | 29,84 | 29,84 | 29,00 | 29,32 | -1,08% | 2,82% | 2.122.700 |
| 19/07/2007 | 29,51 | 29,86 | 29,10 | 29,64 | +1,68% | 2,58% | 1.461.800 |
| 18/07/2007 | 28,83 | 29,23 | 28,56 | 29,15 | +0,87% | 2,32% | 1.204.500 |
| 17/07/2007 | 28,81 | 29,09 | 28,62 | 28,90 | +0,14% | 1,63% | 939.500 |
| 16/07/2007 | 29,17 | 29,17 | 28,67 | 28,86 | -0,99% | 1,71% | 775.600 |